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Original Article 
Purpose: To investigate the surgical, perfusion, and molecular characteristics of glioblastomas 
which influence long-term survival after treatment, and to explore the association between 
MR perfusion parameters and the presence of MGMT methylation and 1p/19q deletions.
Materials and Methods: This retrospective study was approved by our institutional review 
board. A total 43 patients were included, all with pathologic diagnosis of glioblastoma with 
known MGMT methylation and 1p/19q deletion statuses. We divided these patients into long-
term (≥ 60 months, n = 7) and short-term (< 60 months, n = 36) survivors, then compared 
surgical extent, molecular status, and rCBV parameters between the two groups using 
Fisher’s exact test or Mann-Whitney test. The rCBV parameters were analyzed according to 
the presence of MGMT methylation and 1p/19q deletions. We investigated the relationship 
between the mean rCBV and overall survival using linear correlation. Multivariable linear 
regression was performed in order to find the variables related to overall survival.
Results: Long-term survivors (100% [7 of 7]) demonstrated a greater percentage of gross 
total or near total resection than short-term survivors (54.5% [18 of 33]). A higher prevalence 
of 1p/19q deletions was also noted among the long-term survivors (42.9% [3 of 7]) than the 
short-term survivors (0.0% [0 of 36]). The rCBV parameters did not differ between the long-
term and short-term survivors. The rCBV values were marginally lower in patients with MGMT 
methylation and 1p/19q deletions. Despite no correlation found between overall survival and 
rCBV in the whole group, the short-term survivor group showed negative correlation (R2 = 0.181, 
P = 0.025). Multivariable linear regression revealed that surgical extent and 1p/19q deletions, 
but not rCBV values, were associated with prolonged overall survival.
Conclusion: While preoperative rCBV and 1p/19q deletion status are related to each other, 
only surgical extent and the presence of 1p/19q deletion in GBM patients may predict long-
term survival. 
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INTRODUCTION
Glioblastoma (GBM) is a rapidly progressing type of 
primary malignant brain tumor with a mean survival of 
less than 15 months, with only 3-5% of patients surviving 
longer than five years after diagnosis (1, 2). Even in the case 
of surgical resection followed by radiotherapy, most GBM 
patients die within two years from the date of diagnosis, 
and little improvement in brain tumor survival had been 
achieved until the development of chemotherapy with 
temozolomide (TMZ), a DNA alkylating agent. Combining 
radiotherapy with TMZ has been shown to improve 
prognosis and increase overall survival in high grade glioma 
patients (3-9).
In the past, the classification of gliomas has been 
solely based on histological phenotypes. However, an 
increasing body of knowledge on genomics has supported 
the idea that the subtyping of gliomas based on their 
genetic parameters demonstrates better correlation with 
prognosis than did conventional histological subtyping 
(10). Accordingly, recently revised WHO classification 
of gliomas suggested glioma classification based upon 
not only the well-established histologic criteria but also 
upon the genetic characteristics (11, 12). Of the various 
genetic markers related to gliomas, methylation status 
of O-6-methylguanine-DNA methyltransferase (MGMT) 
gene promoter and the status of 1p/19q deletion have 
been suggested to be related to tumor prognosis (13, 14). 
Methylation of the MGMT promoter results in decreased 
levels of MGMT protein, a DNA repair enzyme, thereby 
precipitating tumor cell death. Recent studies have also 
suggested that the methylation of MGMT promoter 
enhances sensitivity to chemotherapy, thus improving 
prognosis with prolonged survival in high-grade glioma 
patients undergoing chemotherapy with TMZ (15, 16). On 
the other hand, co-deletion of 1p19q is a required marker 
for the diagnosis of ‘canonical oligodendroglioma’ and for 
the subclassification of GBM. Accordingly, the presence of 
1p19q codeletion in glioblastoma is demonstrated in GBMs 
with oligodendroglioma background, which are known 
to have better prognoses than classical GBMs (14, 16). 
Nevertheless, there have been conflicting results as to the 
relationship or lack thereof between these two genetic/
epigenetic alterations and the prognosis of GBM (17, 18).
Despite the huge advantage of genetic profiling of GBM 
for prognostication, genomic information from the part 
of GBM is inherently inadequate and does not represent 
the status of the whole GBM, which necessitates the use 
of a non-invasive procedure for the prognostic prediction 
of GBM. Segmentation methods using structural images 
such as T2-weighted images or contrast-enhanced T1-
weighted images have demonstrated clinical utility in the 
measurement of apparent diffusion coefficient (ADC) values 
from glioblastomas (19). Additionally, by using perfusion 
dynamic susceptibility contrast (DSC) MRI, differential 
diagnosis between glioblastoma and primary central 
nervous system (CNS) lymphoma can be achieved with a 
high diagnostic confidence (20). While perfusion DSC-MRI 
has shown a strong correlation between glioma grade and 
rCBV values (21), the relationships between DSC perfusion 
parameters and genetic markers/overall survival are not 
straightforward (22, 23). Beyond MRI, clinical factors, 
such as the extent of resection, are regarded as important 
prognostic factors for GBM (24).
Therefore, we aimed in this study to compare the 
perfusion characteristics of GBMs between long-term (≥ 
60 months) and short-term (< 60 months) survivors using 
DSC-MR perfusion imaging, and aimed to investigate its 
association with MGMT promoter methylation and 1p/19q 
deletion status of GBM, as well as whether preoperative 
DSC parameters are predictive of survival of GBM.
MATERIALS AND METHODS
Subjects
This retrospective study was approved by our institutional 
review board, and informed consent was waived as it was 
a retrospective study. Forty-five patients with pathologic 
diagnoses of glioblastoma (WHO grade IV) on postoperative 
specimen from January 2010 to August 2015 were 
identified. The MGMT promoter methylation and 1p/19q 
deletion statuses from each patient were recorded based on 
their final pathology reports. Two patients were excluded 
because their data on MGMT promoter methylation or 
1p/19q deletion profile was missing. As a result, a total of 
43 patients (26 male and 17 female; mean age, 56.4; age 
range, 14-89 years) were included for baseline analysis.
The overall survival (in months) of each patient was 
calculated from the date of initial brain MRI to either the 
date of the last clinic visit or the date of death. We divided 
the patients into two groups: long-term survivors (≥ 60 
months) and short-term survivors (< 60 months) (16) (Table 1). 
Perfusion MR imaging analyses were performed in 29 
of 43 patients, because 14 patients were excluded due to 
the loss of raw perfusion MR data (Fig. 1). All GBMs were 
www.i-mri.org160
Survival prediction using DSC MRI in GBM | Yong Wonn Kwon, et al.
confirmed at the time of biopsy (n = 1), partial resection (n 
= 1), subtotal resection (n = 8), near total resection (n = 8), 
or gross total resection (n = 11). A neuroradiologist (with 12 
years of neuroimaging experience) retrospectively assessed 
the extent of resection, blinded to clinical information. The 
extent of resection was classified into one of five categories 
based on postoperative magnetic resonance imaging as 
follows: 1) gross total resection (GTR), no visible tumor left; 
2) near total resection (NTR), removal of more than 90% 
but less than 100% of tumor; 3) subtotal resection (STR), 
removal of 50% to 89% of the tumor; 4) partial resection 
(PR), removal of 10% to 49% of the tumor; or 5) biopsy 
(Bx), removal of less than 10% of the tumor (25). The 
standard treatment protocol included radiation therapy plus 
continuous daily TMZ (75 mg/m2 per day) followed by six 
cycles of adjuvant TMZ (150 mg/m2 for five days, every 29 
days) following surgical resection.
MR Examination
The brain MRI protocol included contrast-enhanced 3D T1 
gradient echo images and axial T2* dynamic susceptibility 
weighted-perfusion that was weighted using 3.0T MRI 
scanners (GE Healthcare HDxT and Siemens Skyra). Axial 
T2* DSC-perfusion-weighted imaging (PWI) was performed 
during the administration of gadobutrol (Gadovist; Schering, 
Berlin, Germany; 0.1 mmol/kg of body weight) with an 
injection rate of 3 ml/s followed by a saline flush of 20 cc, 
Fig. 1. Study design diagram.
Table 1. Demographic Characteristics of the Study Subjects
Characteristics
Baseline analysis 
(n = 43)
MR perfusion 
analysis (n = 29)
Sex
Male 60.5% (26/43) 55.1% (16/29)
Female 39.5% (17/43) 44.8% (13/29)
Age (years) 56.4 (14-89)* 57.0 (14-89)*
Overall survival (months)
Long-term survivor 
(≥ 60 months)
16.3% (7/43) 20.7% (6/29)
Short-term survivor 
(< 60 months)
83.7% (36/43) 79.3% (23/29)
Genetic markers
MGMT promoter 
methylation
48.8% (25/43) 55.1% (16/29)
1p / 19q deletions 7.0% (3/43) 6.9% (2/29)
Surgical extent
GTR + NTR** 62.5% (25/40***) 65.5% (19/29)
STR + PR + Bx** 37.5% (15/40***) 34.5% (10/29)
Data are number of patients, and data in parenthesis are percentages except 
where indicated.
*The data is the mean value and the data in parenthesis is range of the values.
** Abbreviations area indicated as follows: GTR = gross total resection; NTR = 
near total resection; STR = subtotal resection; PR = partial resection; Bx = biopsy
*** 40 of 43 patients were evaluated for surgical extent. Three patients who 
could not undergo immediate postoperative (< 24 hours) MRI were excluded 
because the surgical extent could not be accurately measured.
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using the single-shot gradient-echo echo-planar imaging 
sequence (repetition time [TR]/echo time [TE], 1000/18.9 
ms; field-of-view [FOV], 240 mm; slice thickness [ST]/
interslice gap [IG], 7/0 mm; matrix, 256 × 256; flip-angle 
[FA], 60°). 
Immediately following the acquisition of the DSC-PWI, 
the post contrast-enhanced 3D fast spoiled gradient-
recalled acquisition in the steady state (FSPGR), T1-
weighted sequence (TR/TE, 6.2/2.6 ms; FOV, 220 mm; ST/IG, 
1/0 mm; matrix, 512 × 512), or 3D magnetization prepared 
rapid acquisition gradient echo (MPRAGE) sequence (TR/TE, 
1900/2.46 ms; ST, 0.5 mm; matrix, 256 × 256; FA, 9°) was 
obtained. 
Image Preparation - Coregistration of T1 Contrast-
Enhanced MR Images and CBV Map
As the thin-section postcontrast 3D T1 gradient echo 
images and nCBV map differed in slice thickness, the two 
images underwent a coregistration process. Following 
coregistration, the resulting MR images contained both 
structural and functional information regarding the 
tumor characteristics. Coregistration was performed 
using NordicICE (NordicNeuroLab, Norway), a dedicated 
postprocessing software.
Tumor Delineation and Intratumor Segmentation
After successfully performing the coregistration process, 
the region-of-interest (ROI) of the enhancing portion 
of glioblastoma was semi-automatically selected using 
NordicICE. This ROI selection process was performed 
by a neuroimaging researcher with three years of 
neuroimaging experience. Each ROI selection was reviewed 
by a neuroradiologist (with 20 years of neuroimaging 
experience) so as to evaluate its adequacy for analysis. After 
ROI placement was completed in each patient, information 
pertaining to the brain tumor, such as the volume and 
surface area of the brain tumor, as well as statistical 
parameters, such as the mean, median, standard deviation, 
quartiles, and means of the highest/lowest five percentiles, 
were calculated using NordicICE. 
Statistical Analysis
All statistical analyses were performed using SPSS ver. 
20.0. The level of significance was set at P < 0.05. All of the 
continuous variables were tested for normalization. 
The difference in frequencies for the extent of surgical 
resection and for each molecular subtype between long-
term/short-term survivors was evaluated with a Fisher’s 
exact test. A Mann Whitney test was performed in order 
to compare the overall survival (months) according to 
the status of the extent of surgical resection or genetic 
alterations, as well as various rCBV parameters, between 
the long-term and short-term survivors.
Next, in order to explore the relationship between 
imaging markers (rCBV values) and the two genetic markers, 
we compared various rCBV parameters (mean, median, 
5th percentile, 95th percentile, 1st quartile, 3rd quartile, 
minimum, and maximum) according to the status of MGMT 
methylation and 1p/19q deletions. 
In order to explore the relationship between overall 
survival (in months) and mean CBV values, we performed 
linear regression analysis and a Pearson correlation test.
Finally, we performed multivariable linear regression in 
order to find variables related to prolonged overall survival. 
The dependent variable was the overall survival (in months), 
and the enter method was used in the multivariable 
regression. The independent variables selected for analysis 
were the extent of surgical resection, MGMT methylation, 
1p/19q deletions, and mean rCBV.
RESULTS
All of the long-term survivors underwent either GTR 
or NTR (4 GTRs and 2 NTRs), but only 11 of the 23 short-
term survivors underwent GTR or NTR. The overall survival 
was significantly greater in the GTR+NTR group (median, 
32 months; interquartile range [IQR], 18-71 months) than 
in the STR+PR+Bx group (median, 9 months; IQR, 6.5-16 
months; P = 0.00042).
The long-term survivor group (42.9% [3 of 7]) showed a 
greater percentage of 1p/19q deletion than did the short-
term survivor group (0.0% [0 of 36], P = 0.037). As for 
the percentage of MGMT methylation, no difference was 
revealed between the long-term (57.1% [4 of 7]) and the 
short-term survivor groups (58.3% [21 of 36], P = 1.000). 
Between GBM patients with MGMT methylation (median 
27.5 months, IQR 15.5-35.5 months) and those without 
MGMT methylation (median 15 months, IQR 12-40 months), 
there was no difference found in terms of overall survival (P 
= 0.318). However, 1p/19q deleted GBM patients (median 
82 months, IQR 81.5-82.5 months) survived longer than 
patients without 1p/19q deletion (median 22 months, IQR 
11.5-33.5 months, P < 0.01) (Figs. 4-6).  
Regarding rCBV parameters, there was no significant 
difference found between the long-term and short-term 
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survivors (P > 0.05, Table 2). In the context of MGMT 
methylation, the rCBV values were lower in patients with 
MGMT methylation. However, this trend was not statistically 
significant. It should be noted, however, that statistical 
analysis comparing the rCBV parameters in terms of 1p/19q 
deletions was inapplicable, due to the small number of 
1p/19q deleted patients (n = 2) (Table 3) (Figs. 4-6). 
When both the long-term survivor and short-term 
survivor groups were combined into one large group, there 
was no significant linear correlation found between the 
mean rCBV value and overall survival (Fig. 2). However, 
a significant negative linear correlation was observed 
between the mean rCBV value and overall survival in the 
short-term survivor group (adjusted R2 = 0.181, P = 0.025) 
(Fig. 3).
Multivariable linear regression analysis demonstrated 
that our model was able to predict overall survival with 
statistical significance (P = 0.018, adjusted R2 = 0.275). 
Surgical extent and 1p/19q deletion were found to be 
statistically significant variables contributing to prolonged 
overall survival (Table 4).
DISCUSSION
We found that the long-term survivor group of GBM was 
characterized by a higher extent of surgical resection, a 
higher frequency of 1p/19q deletion and a lower tendency 
of some rCBV parameters (95th percentile, 3rd quartile, and 
maximum), but no significant difference was found in terms 
of median rCBV of the tumor as compared to that of the 
short-term survivor group. 
The findings of our study are in accordance with previous 
research suggesting that the presence of 1p/19q deletion 
is a favorable prognostic indicator (26-29). 1p/19q deletion 
is a hallmark of the presence of an oligodendroglial 
Fig. 2. Scatter plot of mean rCBV versus overall survival 
(in months) in GBM patients, including both long-term 
and short-term survivors. Although the scatter plot 
demonstrates a decreasing trend towards lower mean rCBV 
values with greater overall survival, the linear regression 
analysis did not demonstrate a statistically significant linear 
correlation (P = 0.186, R2 = 0.029).
Fig. 3. Scatter plot of mean rCBV versus overall survival 
(in months) in short-term GBM survivors. Linear regression 
analysis demonstrated the presence of a statistically 
significant negative linear correlation between mean rCBV 
and overall survival (P = 0.025, R2 = 0.181).
Table 2. Comparison of Various rCBV Parameters between the 
Long-Term and Short-Term Survivors 
rCBV parameter Long-term (n = 6) Short-term (n = 23) P-value
Mean 2.66 [1.95-3.48] 2.98 [1.52-6.48] 0.148
Median 2.32 [1.44-3.59] 2.84 [1.58-6.48] 0.430
5th percentile 2.32 [1.44-3.59] 2.84 [1.48-6.48] 0.964
95th percentile 5.71 [3.60-8.09] 7.78 [2.29-12.64] 0.072
1st quartile 1.52 [0.95-2.50] 1.38 [0.00-4.81] 0.693
3rd quartile 3.71 [2.74-5.49] 4.49 [1.87-8.55] 0.072
Minimum 0.03 [0.00-0.18] 0.00 [0.00-1.00] 0.953
Maximum 5.71 [3.60-8.09] 7.79 [2.29-12.64] 0.072
Majority of the rCBV values were lower in the long-term survivor group. However, 
Mann-Whitney test failed to reveal any statistically significant difference.
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component, and oligodendroglial background in GBM has 
long been regarded as a predictor for prolonged survival 
(27). The alteration of 1p/19q has reportedly been linked 
with greater sensitivity to chemotherapy with alkylating 
agents (26, 28, 29). However, some reports have not 
found any improved survival in GBM patients with 1p/19q 
deletion (30). These conflicting results on the survival of 
GBM with 1p/19q deletions may be attributable to tumor 
heterogeneity and the near impossibility of whole tumor 
analysis of GBM (31). 
Unlike 1p/19q deletion, MGMT methylation did not show 
a statistically significant difference between the long-
term and short-term survivor groups in our study. Hegi et 
al. (13) discussed that MGMT methylation status serves 
as an independent prognostic factor in GBM patients 
Fig. 4. A 47-year-old male with glioblastoma in the right frontal lobe. (a) T2-weighted image, (b) T1-weighted contrast-
enhanced image, and (c) rCBV map are shown. The mean rCBV value measured from the enhanced part of the tumor was 1.95. 
Molecular analysis revealed both MGMT promoter methylation and 1p19q codeletion. The overall survival was 81 months. 
a b c
Table 3. Comparison of Various rCBV Parameters in Terms of 
MGMT Methylation and 1p/19q Deletions
rCBV parameter Group Group P-value
MGMT 
methylation
With MGMT 
methylation (n = 16)
Without MGMT 
methylation (n = 13)
Mean 2.71 [1.52-3.58] 2.99 [1.85-6.48] 0.148
Median 2.63 [1.58-3.68] 2.59 [1.44-6.48] 0.430
5th percentile 0.36 [0.00-1.69] 0.44 [0.00-2.88] 0.964
95th percentile 5.45 [2.29-12.64] 8.09 [3.73-12.52] 0.072
1st quartile 1.37 [0.00-2.95] 1.68 [0.00-4.81] 0.693
3rd quartile 3.74 [1.87-7.07] 5.00 [2.55-8.55] 0.072
Minimum 0.00 [0.00-1.12] 0.00 [0.00-1.07] 0.953
Maximum 5.45 [2.29-12.64] 8.09 [3.73-12.51] 0.072
1p/19q deletion 
status
With 1p/19q 
deletions (n = 2)
Without 1p/19q 
deletion (n = 27)
Mean 2.34 [1.95-2.73] 2.92 [1.52-6.48]
N/A**
Median 1.71 [1.43-2.00] 2.68 [1.44-6.48]
5th percentile 0.51 [0.50-0.53] 0.43 [0.00-2.88]
95th percentile 5.84 [3.60-8.09] 6.60 [2.29-12.64]
1st quartile 1.16 [0.95-1.37] 1.51 [0.00-4.81]
3rd quartile 4.11 [2.73-5.48] 4.23 [1.87-8.55]
Minimum 0.08 [0.00-0.15] 0.00 [0.00-1.12]
Maximum 5.84 [3.60-8.09] 6.60 [2.29-12.64]
** Mann-Whitney test was inapplicable in terms of 1p/19q deletions due to 
limited sample size.
Table 4. Multivariate Analysis of Predicting Overall Survival in 
Terms of Surgical Extent, 1p/19q Deletion, MGMT Methylation, 
and Mean rCBV
Variables Adjusted R2
P-value, 
univariate
P-value, 
multivariate
Surgical extent 0.163 0.017 0.042
1p/19q deletions 0.188 0.011 0.039
MGMT methylation -0.035 0.826 0.490
Mean rCBV 0.029 0.186 0.273
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who undergo chemotherapy with alkylating agent, which 
contradicts the findings of our study. However, according 
to a meta-analysis conducted by Meng et al. (32), the 
prognostic significance of MGMT promoter methylation 
in terms of overall survival was not as remarkable in the 
Asian population as it was in the European or American 
populations. Our study results comparing the proportion of 
MGMT methylation between the long-term and short-term 
survivors were in line with Meng’s results. 
Regarding PWI, the long-term survivor group tended to 
show lower mean rCBV values (95th percentile, 3rd quartile, 
and maximum values) than did the short-term survivor 
group, but this trend was not statistically significant. 
In a recent study, rCBV was shown to be a significant 
predictor of progression-free survival both prior to and 
after anti-angiogenic therapy (33). However, findings on 
the relationship between rCBV and overall survival, have 
not been straightforward (34, 35). The tendency of lower 
Fig. 5. A 73-year-old male with glioblastoma in the left temporal lobe. (a) T2-weighted image, (b) T1-weighted contrast-
enhanced image, and (c) rCBV map are shown. The mean rCBV value measured from the enhanced part of the tumor was 2.70. 
Molecular analysis revealed that both MGMT promoter and 1p19q were intact. The overall survival was 13 months.
a b c
Fig. 6. A 43-year-old female with glioblastoma in the right frontal lobe. (a) T2-weighted image, (b) T1-weighted contrast-
enhanced image, and (c) rCBV map are shown. The mean rCBV value measured from the enhanced part of the tumor was 3.48. 
The molecular analysis revealed that both MGMT promoter and 1p19q were intact. The overall survival was 106 months.
a b c
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mean rCBV values found in our long-term survivor group 
may suggest a complex role of rCBV and vascularity in the 
overall survival of GBM. 
In terms of the relationship between genetic markers and 
imaging markers, we found that GBM patients with 1p/19q 
deletion showed longer survival than those without 1p/19q 
deletion. Moreover, despite a limited sample size, 1p/19q 
deleted patients seemed to demonstrate lower CBV values 
overall. This result appears to be somewhat counterintuitive, 
given that the presence of 1p/19q deletion, a molecular 
marker for oligodendroglial background, is related to 
higher rCBV values (36, 37). In a study comparing rCBV 
values between WHO grade II astrocytoma and WHO grade 
II oligodendroglioma (36), a higher average rCBV value 
was noted in the oligodendrogliomas. In another study 
comparing rCBV between oligodendroglial tumors with 
1p/19q deletion and those with intact 1p/19q, the presence 
of 1p/19q deletion was related to higher rCBV (37). Unlike 
previous studies, our study only included the GBM patients 
in which 1p/19q deletion could not be determined with the 
same accuracy as the low-grade oligodendrogliomas, due 
to tumor heterogeneity of GBM (17). A further study with a 
larger case series is warranted in the near future. 
GBM patients with MGMT methylation demonstrated lower 
rCBV values than nonmethylated patients, although this 
trend was not statistically significant. These findings were 
consistent with those of a previous study showing that the 
MGMT status of GBM was not related to the rCBV (15).
In our study, the relationship between the overall 
survival and the mean CBV did not represent a completely 
linear function. When short-term survivors are considered 
separately, however, the lower values of rCBV tended to 
correlate with prolonged survival. According to Bonekamp et 
al. (38), preoperative perfusion MRI showed that an elevated 
CBV value was associated with worse overall survival. 
Interestingly, Bag et al. (22) demonstrated that there was a 
statistically significant association between posttreatment 
perfusion parameters and overall survival (OS), but that 
there was no such association between pre-treatment 
perfusion parameters and OS. In our study, multivariable 
linear regression even confirmed that surgical extent and 
1p/19q deletion are the only meaningful prognostic factors 
for glioblastoma overall survival. Thus, our results contradict 
those of the recent systemic review claiming that rCBV is a 
good predictive/prognostic marker (pooled hazard ratio of 
0.47 for overall survival) (23). A further study with a larger 
sample size for the long-term survivor group is needed in 
the future in order to address these conflicting results. 
This study has several limitations: The first limitation is 
the retrospective nature and small sample size of the study. 
The second limitation is that this study focused mainly on 
the association between rCBV parameters measured on 
tumor ROIs and their molecular subtypes. Other factors 
that might have influenced patient survival, such as the 
socioeconomic status and general condition of each patient, 
were not extensively taken into account. Statistical analysis 
in terms of 1p/19q deletion was inapplicable due to a small 
sample size (n = 2). However, our 1p/19q-deleted patients 
demonstrated prolonged overall survival and lower rCBV 
values than did 1p/19q nondeleted patients.
We believe our findings demonstrate the significance 
of perfusion parameters of GBMs and its relationship to 
genetic parameters such as MGMT methylation and 1p/19q 
deletion status in terms of the overall survival of GBM 
patients. 
In conclusion, our study showed that being a long-term 
survivor (≥ 60 months) of GBM is significantly associated 
with surgical resection and 1p/19q deletion status of the 
tumor, as well as a tendency of lower rCBV (95th percentile, 
3rd quartile, and maximum) values of preoperative PWI, 
but this trend is not statistically significant. Surgical extent 
and the presence of 1p/19q deletion in GBM patients may 
predict long-term survival. 
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